At a press conference launching Myozyme in early May, Academia Sinica president Lee Yuan-tseh stated that while in the past Taiwan lacked the ability to develop new drugs, dictating that it rely on foreign certification, the capabilities of the country's academic institutions and industry have already improved to the point that the government's regulatory system needs to be adjusted.
5 月初，中研院院長李遠哲在 Myozyme 發表記者會上表示，過去台灣研發新藥實力不足時，需處處仰賴外國的查驗鑑定，如今學界、業界的能力已經提升，政府管理的配套措施也應該有所調整。